Shares of Profound Medical Corp. (TSE:PRN - Get Free Report) dropped 0.2% on Tuesday . The stock traded as low as C$10.30 and last traded at C$10.30. Approximately 9,329 shares were traded during mid-day trading, an increase of 33% from the average daily volume of 7,004 shares. The stock had previously closed at C$10.32.
Profound Medical Stock Down 0.2 %
The firm has a market capitalization of C$252.14 million, a PE ratio of -6.20 and a beta of 0.81. The firm's 50 day moving average price is C$11.26 and its two-hundred day moving average price is C$11.56. The company has a quick ratio of 14.98, a current ratio of 8.61 and a debt-to-equity ratio of 16.95.
Profound Medical (TSE:PRN - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported C($0.38) earnings per share for the quarter, meeting the consensus estimate of C($0.38). The firm had revenue of C$3.06 million during the quarter, compared to analysts' expectations of C$3.42 million. As a group, research analysts forecast that Profound Medical Corp. will post -1.9000001 EPS for the current fiscal year.
Insider Activity at Profound Medical
In related news, Senior Officer Rashed Osman Dewan purchased 9,765 shares of the business's stock in a transaction that occurred on Thursday, August 15th. The shares were purchased at an average cost of C$12.85 per share, with a total value of C$125,480.25. 8.62% of the stock is currently owned by corporate insiders.
About Profound Medical
(
Get Free Report)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Profound Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Profound Medical wasn't on the list.
While Profound Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
